- World Pharma News Home » Corporate » Boehringer Ingelheim signs a license agreement with Evec Inc. for its fully-human antibody programme
(a free service delivered by FeedBurner)
Boehringer Ingelheim signs a license agreement with Evec Inc. for its fully-human antibody programme
Boehringer Ingelheim has signed a licence agreement with Evec, Inc., Japan, for one of its fully-human therapeutic antibody programmes. Based on the agreement, Boehringer Ingelheim will obtain worldwide exclusive development and commercialisation rights for the complete programme. In return, Evec expects to receive an upfront payment and milestone payments depending on development phases from Boehringer Ingelheim totalling up to EUR 55 million, as well as royalty payments associated with potential product sales. Further financial details have not been disclosed.
Discuss Add this link to... Bury
Comments